

ERROR CORRECTION FORM

Sequence Number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

CIBMTR Recipient ID:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Initials:

--	--

Today's Date:

		2	0		
Month	Day	Year			

Infusion Date:

		2	0		
Month	Day	Year			

CIBMTR Center Number:

--	--	--	--	--	--



Wiscott-Aldrich Syndrome Post-HSCT Data

Registry Use Only

Sequence Number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Date Received:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

CIBMTR Center Number:

--	--	--	--	--	--

CIBMTR Recipient ID:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Today's Date:

		2	0		
Month	Day	Year			

Date of HSCT for which this form is being completed:

Month	Day	Year			

HSCT type: autologous allogeneic, unrelated allogeneic, related syngeneic (identical twin)

Product type: marrow PBSC cord blood other product, specify: _____

Visit: 100 day 6 month 1 year 2 years > 2 years, specify: _____

To be completed in conjunction with a Form 2100 – 100 Days Post-HSCT Data, Form 2200 – Six Months to Two Years Post-HSCT Data, or Form 2300 – Yearly Follow-Up for Greater Than Two Years Post-HSCT Data. Information reported here should reflect the date of last contact as reported in the post-HSCT data collection form, or immediately prior to death.

Status of Hematologic Engraftment

This section refers to quantitative analyses utilizing discriminating DNA markers. Peripheral blood cells must undergo separation or sorting into T, B, or lymphoid vs. myeloid populations to perform this determination. If RFLP analyses indicate only donor type hematopoiesis, mark T-cell, B-cell, and myeloid as "predominantly or completely donor."

- What is the current status of T-cell engraftment?
 - predominantly or completely donor ($\geq 80\%$ donor chimerism)
 - mixed chimerism (5–80% donor)
 - only host T-cells detected
 - unknown
- What is the current status of B-cell engraftment?
 - predominantly or completely donor ($\geq 80\%$ donor chimerism)
 - mixed chimerism (5–80% donor)
 - only host B-cells detected
 - unknown
- What is the current status of myeloid engraftment?
 - completely donor
 - mixed chimerism
 - completely host
 - unknown

Status of Immunologic Reconstitution

- What is the current mitogen proliferation response? (Refers to response of lymphocytes to phytohemagglutinin, concavalin A or pokeweed mitogen.)
 - absent ($\leq 10\%$ normal response)
 - decreased (11–60% normal response)
 - normal
 - unknown

ERROR CORRECTION FORM

Sequence Number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

CIBMTR Recipient ID:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Initials:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Today's Date:

				2	0				
Month	Day	Year							

Infusion Date:

				2	0				
Month	Day	Year							

CIBMTR Center Number:

--	--	--	--	--	--	--	--	--	--

CIBMTR Center Number:

--	--	--	--	--	--	--	--	--	--

CIBMTR Recipient ID:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

5. What is the current natural killer cell function? (*Refers to specific cytolysis of NK-sensitive target cells, e.g. K562.*)
- 1 absent ($\leq 10\%$ normal response)
 - 2 decreased (11–60% normal response)
 - 3 normal
 - 4 unknown
6. What is the current IgG level?
- 1 absent ($\leq 10\%$ normal level)
 - 2 decreased
 - 3 normal
 - 4 increased
 - 5 unknown
7. What is the current IgM level?
- 1 absent ($\leq 10\%$ normal level)
 - 2 decreased
 - 3 normal
 - 4 increased
 - 5 unknown
8. What is the current IgA level?
- 1 absent ($\leq 10\%$ normal level)
 - 2 decreased
 - 3 normal
 - 4 increased
 - 5 unknown
9. What is the current IgE level?
- 1 absent ($\leq 10\%$ normal level)
 - 2 decreased
 - 3 normal
 - 4 increased
 - 5 unknown
10. What is the current specific antibody response to any antigen against which the recipient has been adequately immunized (e.g., > 3 DPT)?
- 1 absent ($\leq 10\%$ normal response)
 - 2 decreased
 - 3 normal
 - 4 increased
 - 5 unknown
11. What was the platelet count at the date of the most recent follow-up?
- 1 decreased
 - 2 normal
 - 3 unknown
12. What was the platelet size at the date of the most recent follow-up?
- 1 decreased
 - 2 normal
 - 3 unknown

ERROR CORRECTION FORM

Sequence Number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

CIBMTR Recipient ID:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Initials:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Today's Date:

				2	0				
Month	Day	Year							

Infusion Date:

				2	0				
Month	Day	Year							

CIBMTR Center Number:

--	--	--	--	--	--	--	--	--	--

CIBMTR Center Number:

--	--	--	--	--	--	--	--	--	--

CIBMTR Recipient ID:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

13. Since the date of the last report, has the recipient developed an EBV-associated B-cell lymphoproliferative disorder?

1 yes

2 no

3 unknown

14. Specify the date of diagnosis:

				2	0				
Month	Day	Year							

15. Signed: _____

Person completing form

Please print name: _____

Phone number: (_____) _____

Fax number: (_____) _____

E-mail address: _____